Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?

Autor:	Coline H.M. van Moorsel, Heleen A. Crommelin, Ger T. Rijkers, Bob Meek, Jan C. Grutters, Anke M.E. Claessen, Daniëlle Hijdra, Adriane D.M. Vorselaars
Rok vydání:	2016
Předmět:	musculoskeletal diseases 0301 basic medicine Pulmonary and Respiratory Medicine Infliximab therapy medicine.medical_specialty Sarcoidosis Gastroenterology Monocytes 03 medical and health sciences Leukocyte Count 0302 clinical medicine Fluorodeoxyglucose F18 Internal medicine medicine Humans skin and connective tissue diseases medicine.diagnostic_test business.industry Receptors IgG Case-control study medicine.disease Prognosis Infliximab Antirheumatic Agents stomatognathic diseases 030104 developmental biology 030228 respiratory system Positron emission tomography Case-Control Studies Positron-Emission Tomography Radiopharmaceuticals business medicine.drug
Zdroj:	The European respiratory journal. 48(4)
ISSN:	1399-3003
Popis:	Responders to infliximab therapy have more intermediate monocytes at baseline compared with non-responders http://ow.ly/fMLp300oVrO
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bb92f81e185a464a86755a8b6fb8b6 https://pubmed.ncbi.nlm.nih.gov/27390275 Zobrazit plný text záznamu